Iain McCulley (CMgr FCMI)’s Post

Transcript

Hello and welcome to Ian's Industry Insights. Hope you've all had a fantastic start to the week. As ever, we'll look to bring you some of the latest investment, innovation and industry insights from within the medtech sector. I want to start today just by drawing your attention to our Lift Up Live event happening later on today, 4:15 PM UK time. And it's all about the importance of personal branding and how you can build your own legacy. We've got some phenomenal guests as you can see. Lined up and really worthwhile signing up for this one. Obviously. If you can join us live, please do you have opportunity to ask the guest questions in real time? Even if you can't, well worth signing up because you have access to the recording afterwards. That's 4:15 PM UK time. You can see some of the times across America and Europe as well. But definitely do join if you're able to later on today. Starting with some of the investment and we've seen the XS innovations have raised ���1.1 million for its vascular access design device. Sorry. So this is all about improving treatment for end stage kidney disease patients and obviously really exciting to see. You can see globally approximately 4 million patients are affected by end stage kidney disease with 70% of them relying on hemodialysis as a vital component of the treatment. So. They say that the conventional high flow vascular access sites required for hemodialysis often lead to severe complications such as vascular access, occlusion, so heart failure and still syndrome as well. So this is a really, really exciting innovation from excess innovations and great to see that they've raised the capital hopefully to further develop that device. We've seen GT Medical Technologies have brought in $35 million for its bioresorbable radiation tile. This is a venture loan facility. And you can see that this includes some brilliant venture partners. You've got MVM Partners, Glide HealthCare Partners, Medtech Venture Partners and Bluestone Venture Partners. And you can see from Pearl Ango, the CEO, how delighted they are to have the kind of support to expand the reach of their innovative targeted radiation. Dilution. So congratulations obviously to to all involved GT medical technologies and we look forward to seeing how that investment is going to further enhance that technology. We've also seen J&J have led a $50 million financing for an imaging company called Spectra Wave. So this is a Series B round and is all about their commercial expansion and product additions for spectral wave and they're using this in the treatment of coronary artery disease. So really cool technology and advancements from Spectra Wave and no real surprise that it's drawn the attention that it has. So as I say, we've seen. Grand Jays venture capital arm heavily involved in this and I think clearly some exciting technology. They've already had an initial launch in the US and so now they're looking to increase their capabilities, sorry, even further. So in addition to J&J innovation, it's also worth mentioning that S3 Ventures, Lumira Ventures, SV Health, Deerfield Management, No Adventure, Heartwork Capital and some undisclosed parties were involved in that. Around as well. So congratulations to Spectra Wave, look forward to seeing that investment leveraged. We've seen Edge Medical Ventures as well has launched a $70 million Med tech fund. So Edge Medical Ventures have basically done this on the back of a dearth of of capital for novel ideas emerging from the Israeli medtech ecosystem. So the fund is looking to invest in founders regardless of geography targeting companies. Developing medical device technologies, particularly in vascular interventions, urology, gastro intense intestinal, Women's Health, home treatment, imaging and minimal invasive surgery. So good to see further funds generated and and obviously I'm sure many companies will be looking to access that. Short summary on some of the August deals that we've seen as well. So we've seen that the Med Tech deal values tipped about $1.73 million in August, which is the lowest monthly total seen in 2024. But this is focused on particular VC deals. Obviously, we have seen an uptick in maybe other acquisitions in general, so it wouldn't necessarily read so much into that. Additionally, we've seen Boston Scientific and Silk Road saying that they expect to close their merger in the coming days. So it's basically said in the securities filing that the antitrust waiting period expired Thursday evening, opening the door to complete the 1.26 billion deals. So we have featured this acquisition or this merger previously, but just wanted to share the update. This looks like it's very close to closing in the coming days. We've seen additionally then moving into. Some of the kind of advancements, latest innovation that Zambon have announced success with this aerosol device trial. So this is all about a study that met the primary endpoint finding the company's aerosol delivery system safe and effective in treating non cystic fibrosis bronchitis. So obviously really exciting to to see this kind of novel technology and see the positive results. So we'll be keeping a very, very keen eye on what Zambon will do. Um, beyond that? We've seen Penumbra have received CE Mark for its Lightning Flash 2.00 and it's Lightning Bolt 7. So it says that the Lightning Flash 2.0 will be the most advanced thrombectomy system in the European market to address Venus and pulmonary from US so. It's really good to see that they asked, they've kind of prioritized that CE marking in Europe. And I think it's great to see this kind of expansion and and those novel technologies hitting the European market. So good work by all involved at Penumbra. We also have Biotronic have earned an expanded FDA nod for for pacing lead delivery capita system. So it announced that its approval had. Basically the new labeling for the pacing combination makes the products the 1st and only stylet driven lead. And dedicate lead and dedicated delivery capital system approved by the FDA. So obviously a, a huge coup for for Biotronic. And I think they've got a real opportunity now to yeah, really establish themselves as, as market leaders there. You would have seen last week I mentioned about Apple's looking to get FDA approval actually for two things for their hearing aids software and also for sleep apnea. They have one FDA approval for the hearing aid software for certain Air Pods. So it's the first company to receive authorization for over the counter hearing aid software. So this is a huge moment in the industry. We spoke about last week how this the impact I guess this could. Have on the wider market if Apple are successful. And so I think it's gonna be really interesting to see now as I say, what this means for I guess over the counter hearing aid market and that wide or wearable industry and how that can actually translate into actual regulated medical devices as well. So yeah, really interesting to see and I think a really positive advancement in the industry. 3D Systems have received FDA clearance for an ankle replacement solution, and this will pair with Smith and Nephew's Total Total Ankle Replacement solution, designed to help surgeons save time and ensure accuracy while performing fewer steps with standard instrumentation. So, yeah, obviously really exciting for 3D Systems, the fact they've got that FDA approval and the fact that obviously they'll be able to use that with Smith and nephews. Ankle solution that is a huge step forward for 3D Systems and their technology has really evolved over the last few years. So congratulations to all involved there. Final one this week and we've seen that the analysis from Thermology Health Imaging Tech capable Analysis, sorry, has found that Thermology Health Imaging Tech is capable of saving the NHS ��1 billion. So we've seen that basically. It's technology for screening and detecting diabetic foot ulcers has a potential to not only improve patient outcomes, but to enable cost savings for the NHS of more than ��200 million each year over the next five years. So this is obviously substantial. We talk all the time about unmet needs and I guess the financial element that needs to be applied for anything that's going to be successful going into healthcare settings, particularly in the NHS at the moment and the. Guys aren't alone with that, but this is just an incredible statement and so I think we'll be keeping a very keen eye on how this may be embedded, what the results may well look like and certainly, as I say, could be quite substantial for both for thermology health and obviously for the NHS as well. That is all for this week. One final reminder that later today, 4:15 PM lift up will be going live. Well worth. Growing up and hope as many of you as possible can join. Other than that, have a fantastic week ahead. Look forward to speaking to some of you soon and keep on making a difference. Thank you.